Dosing Completed in Phase 1 Study of GTP-004 for Myasthenia Gravis Treatment Side Effects
Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s…